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Available online 6 January 2016Chromatin accessibility is tightly regulated by multiple factors/mechanisms to establish different cell type-
speciﬁc gene expression programs from a single genome. Dysregulation of this process can lead to diseases in-
cluding cancer. The Mi-2/nucleosome remodeling and deacetylase (NuRD) complex is thought to orchestrate
chromatin structure using its intrinsic nucleosome remodeling and histone deacetylase activities. However, the
detailed mechanisms by which the NuRD complex regulates chromatin structure in vivo are not yet known. To
explore the regulatory mechanisms of the NuRD complex, we mapped genome-wide localization of MBD3, a
structural component of NuRD, in a human breast cancer cell line (MDA-MB-231) using a modiﬁed ChIP-seq
protocol. Our data showed high quality localization information (i.e., high mapping efﬁciency and low PCR
duplication rate) and excellent consistency between biological replicates. The data are deposited in the Gene
Expression Omnibus (GSE76116).
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2.1. Cell culture
Human breast cancer cells (MDA-MB-231) were obtained from the
American Type Culture Collection (ATCC) and maintained in DMEMBiology Laboratory, National
ander Drive, Research Triangle
ss article under the CC BY-NC-ND lice(Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen)
at 37 °C in a 5% CO2 atmosphere.
2.2. Cell ﬁxation
Sub-conﬂuent MDA-MB-231 cells (two 15 cm dishes, treated
separately) were washed twice with PBS, trypsinized, collected by
centrifugation andwashed once againwith PBS. Cellswere resuspended
in 10 mL of 1% formaldehyde-PBS and incubated with constant inver-
sion for 10 min at room temperature. To terminate ﬁxation, 2 mL of
2 M Glycine was added to the solution and incubated for another
5 min at room temperature. Cells were divided into 3 tubes, washed
twice with ice-cold PBS and stored at−80 °C until use.
2.3. Chromatin immunoprecipitation
To perform high quality ChIP-seq, we introduced two major
modiﬁcations to a standard ChIP/ChIP-seq protocol [1]. First, we omitted
sodium dodecyl sulfate (SDS) from all procedures because SDS can
compromise the antibody-target protein interaction. Second, we
incorporated a micrococcal nuclease (MNase) digestion step prior to
chromatin fragmentation to maximize protein extraction efﬁciency.
Detailed procedures are described below.
Fixed cells were thawed on ice and resuspended in 1 mL of ice-cold
TM2 (10mMTris, pH 7.4, 2 mMMgCl2) supplemented with 0.6% NP-40
and protease inhibitor [2]. After 10 min incubation on ice, cells were
washed once with ice-cold TM2 and resuspended in MNase digestionnse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Basic quality score for ChIP-seq data.
Sample Sequencing type Raw read pairs (a) Uniquely mapped pairs (b) (b/a) % Non-duplicate pairs (c) (c/b) %
Replicate 1 Paired-end 50,887,944 35,909,398 70.57% 29,442,026 81.99%
Replicate 2 Paired-end 74,312,781 51,458,955 69.25% 44,711,162 86.89%
Fig. 1. An example in UCSC genome browser format. MBD3 binding pattern at VCAN gene is shown (two biological replicates; MBD3 rep1 and MBD3 rep2).
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MNase). After thorough mixing, cells were digested at 37 °C for 3 min
and then immediately placed on ice. To stop MNase digestion, 20 μL of
0.5 M EDTA was added. After 10 min incubation on ice, cells were cen-
trifuged and resuspended in 1mL of fragmentation buffer (TM2 supple-
mented with 600 mM NaCl, 1% Triton-100, 0.1% sodium deoxycholate,
and protease inhibitor) and incubated on ice for 20 min. Then, cells
were fragmented using focused-ultrasonication (Covaris) under the fol-
lowing conditions: 12 × 12mm round-bottom glass tube (cap with AFA
ﬁber), Duty Cycle 20%, Peak incident Power 145 Watts, cycles per burst
200, time 15min, Bath Temperature 4 °C. The unsoluble fractionwas re-
moved by centrifugation and supernatant was collected as the chroma-
tin fraction. The NaCl concentration was adjusted to 150 mM by adding
TM2 supplemented with protease inhibitor. After 5 min incubation on
ice, any unsoluble proteins were removed by centrifugation. Chromatin
(600 μL) was incubated with 3 μg of anti-MBD3 antibody (Abcam,
ab91458) at 4 °C for 16 h. After adding 15 μL of blocked Dynabeads pro-
tein A/G, chromatin fraction was further incubated at 4 °C for 1.5 h.
Beads were washed three times with SDS-free RIPA buffer (25 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate),
three times with SDS-free high salt RIPA buffer (25 mM Tris–HCl,
pH 7.4, 600 mM NaCl, 1% NP-40, 1% sodium deoxycholate), and once
with EB (10 mM Tris, pH 7.4).
2.4. Library preparation and sequencing
Washed beads were resuspended with Transposase buffer (20 μL of
1 × tagmentation buffer, 10 μL of Nextera XT transposase, 10 μL of EB)
and incubated at 37 °C for 30 min. Beads were washed twice with
SDS-free RIPA buffer, resuspended in 200 μL of SDS-free RIPA buffer,
and incubated at 65 °C for 45min. Samples were then treated with pro-
teinase K, and the DNA was puriﬁed using DNA Clean & Concentrato-5
(Zymo Research) and eluted in 28 μL resuspension buffer. DNA wasampliﬁed and puriﬁed using standard NexteraXT PCR conditions with-
out any modiﬁcations. The resulting libraries were sequenced on the
Illumina NextSeq 500 paired-end system at the NIEHS Epigenomics
Core Facility.
2.5. Sequencing data processing for quality control
Sequencing reads were quality ﬁltered, adapter trimmed, and
mapped to human reference genome (UCSC assembly hg19, GRCh37)
using Bowtie (version 0.12.8) [3]. The non-duplicate uniquely mapped
reads were selected with the Picard tool (http://picard.sourceforge.
net) and used for subsequent analysis. Basic quality control data are
provided in Table 1. To make coverage tracks, the paired-end reads
were merged into single fragments and converted to bigwig ﬁles. An
example locus showing MBD3 enrichment is depicted in genome
browser format (Fig. 1).
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